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Abstract
Pathogenic variants in the Golgi localised alpha 1,6 fucosyltransferase, FUT8,
cause a rare inherited metabolic disorder known as FUT8-CDG. To date, only
three affected individuals have been reported presenting with a constellation of
symptoms including intrauterine growth restriction, severe delays in growth
and development, other neurological impairments, significantly shortened
limbs, respiratory complications, and shortened lifespan. Here, we report an
additional four unrelated affected individuals homozygous for novel patho-
genic variants in FUT8. Analysis of serum N-glycans revealed a complete lack
of core fucosylation, an important diagnostic biomarker of FUT8-CDG. Our
data expands both the molecular and clinical phenotypes of FUT8-CDG and
highlights the importance of identifying a reliable biomarker for confirming
potentially pathogenic variants.
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1 | INTRODUCTION
Congenital disorders of glycosylation (CDG) are a clinically
diverse group of primarily autosomal recessive
disorders that result in altered protein and lipid glycosyla-
tion. To date, more than 135 genes have been found to
cause CDG.1,2 Several of these disorders are specifically due
to abnormalities in fucosylation, which is an enzymatic
process of incorporating the monosaccharide L-fucose into
the N- and O-glycans of proteins or glycolipids.3
Proper fucosylation requires the formation of the acti-
vated donor substrate, guanosine diphosphate L-fucose
(GDP-fucose), which can occur by both de novo and sal-
vage mechanisms.3 It is widely believed that the de novo
pathway accounts for the vast majority (90%) of GDP-
fucose generated within a cell.4 In the de novo pathway,
glucose and mannose are essential for synthesising GDP-
mannose, of which a portion is subsequently converted
to GDP-fucose via a two-enzyme mechanism involving
GDP mannose 4,6-dehydratase (GMDS), and GDP-keto-
6-deoxymannose 3,5 epimerase (TSTA3) (aka FX pro-
tein).3 The salvage pathway also utilises a two-enzyme
mechanism to convert exogenously provided (diet) or
recycled L-fucose (lysosomal-dependent glycan degrada-
tion) to GDP-fucose. Here, L-fucose is first phosphory-
lated by fucose kinase (FCSK) to generate fucose-
1-phosphate which then undergoes a pyrophosphorylase
(FPGT) reaction to yield GDP-fucose.3,5 Postnatal lethal-
ity in a Tsta3 (aka FX) knockout (KO) mouse model has
shown that complete loss of the de novo pathway can be
rescued by providing exogenous L-fucose, suggesting a
compensatory role of the salvage pathway.6 Ultimately,
GDP-fucose is transported into the Golgi via SLC35C1 or
into the endoplasmic reticulum by SLC35C2 where spe-
cific fucosyltransferases add fucose to various acceptor
substrates.7,8
The most ubiquitous form of fucosylation is “Core
fucosylation” of N-linked glycans and requires the Golgi
localised fucosyltransferase FUT8 to attach an L-fucose to
the N-acetylglucosamine (GlcNAc) directly linked to an
asparagine (Asn)3 (Figure 1A). FUT8 contains three dis-
tinct domains, an N-terminal coiled-coil domain, a
glycosyltransferase 23 family domain and a C-terminal
SH3 domain. It is unclear what role the coiled-coil or
SH3 domains of FUT8 play in its function. Although, if
compared to other proteins containing these domains,
they likely are involved in protein-protein interactions.10
Core fucosylation has been shown to be critical for many
cellular processes including immune system regulation,
inflammatory responses, cancer metastasis, and embry-
onic development.11-15
Thus far, biochemically confirmed pathogenic variants
have been identified in fucose kinase (FCSK) [OMIM
#618324], fucosyltransferase 8 (FUT8) [OMIM# 618005],
GDP-fucose transporter (SLC35C1) [OMIM# 605881], pro-
tein O-fucosyltransferases (POFUT1) [OMIM# 615327],
fucose-specific beta-1,3-N-acetylglucosaminyltransferase
(LFNG) [OMIM# 609813], and the lysosomal fucosidase
1 (FUCA1) [OMIM# 612280]. All are extremely rare disor-
ders, and only a few SLC35C1-CDG individuals have been
shown to benefit from oral fucose therapy.16
Here, we identify four unreported FUT8-CDG sub-
jects expanding this disorder's molecular and clinical
presentation.
2 | METHODS AND MATERIALS
2.1 | Clinical data
Written consent was provided for all four families in
accordance with a Sanford Burnham Prebys Medical Dis-
covery Institute approved IRB-2014-038-17.
2.2 | Serum N-glycan analysis
Matrix-assisted laser desorption/ionisation tandem time
of flight/time of flight (MALDI-TOF/TOF) mass spec-
trometry analysis of total serum N-glycans was performed
as previously described at the Mayo Clinic.17
2.3 | Exome sequencing and analysis
All four affected individuals had next generation
sequencing performed by different institutions. CDG-
0099 had whole genome trio sequencing performed in a
research setting, while CDG-0108 had whole exome
sequencing (WES) performed by a CLIA approved clini-
cal lab service. Specifically, for CDG-0095 and 0096,
genomic DNA was extracted from blood and used
for WES on an Illumina NextSeq500 instrument
with 150-nucleotide paired-end sequencing. WES raw
data were processed and analysed with BWA aligner
(19451168), GATK (20644199), and ANNOVAR
(20601685). All variants were confirmed by Sanger
sequencing.
3 | RESULTS
3.1 | Clinical phenotype
CDG-0095 is a female infant of Iranian ancestry born to
consanguineous second-degree cousins (Figure 1B). The
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family history was notable for an affected sibling with simi-
lar presentation who passed away at 14 months of age with-
out a diagnosis. The pregnancy was complicated by
polyhydramnios. However, there was no evidence of
intrauterine growth restriction (IUGR) on prenatal ultraso-
nography. She was unable to tolerate breastfeeding and had
hypotonia and dysmorphic features on physical examina-
tion (Table 1). She had global developmental delays with
cognitive impairment and epilepsy. She had a history of
recurrent pneumonia. She is still alive at 3 years of age.
The second individual, CDG-0096, is a male also of
Iranian descent and a product of a second-degree consan-
guineous marriage (Figure 1B). The pregnancy was not
complicated by polyhydramnios or IUGR, but he was
delivered at 37 weeks gestation by caesarean section due
to meconium aspiration. During the postnatal period, he
was hypotonic and could not tolerate breast feeding. He
was also found to have dysplastic ears and dysmorphic
facial features. He has a history of developmental delays
with severe intellectual disability and epilepsy that is only
partially controlled with medication (Table 1). Brain mag-
netic resonance imaging revealed slight ventriculomegaly
with mildly delayed myelination. Abdominopelvic ultraso-
nography showed renal stones in both kidneys without
any evidence of hepatosplenomegaly. The individual has
had recurrent pneumonia for which he was admitted to
hospital on two occasions. Thyroid-stimulating hormone
level (8.1 μU/mL, reference range: 0.3-5.5 μU/mL) was
mildly increased. He remains alive at 6 years of age.
The third individual, CDG-0099, is an affected female
from healthy non-consanguineous parents of European
ancestry who did not have a family history of a similar
disorder (Figure 1B). No pregnancy complications were
reported; however, IUGR was noted. She presented early
with significant hypotonia, facial dysmorphism, failure to
thrive, and feeding problems requiring placement of a
FIGURE 1 Identification of novel FUT8 pathogenic variants in four unrelated families. A, Schematic showing the FUT8-dependent
synthesis of core fucose. B, Pedigrees for the four families. C, Schematic showing both new (upper) and previously reported (lower)
mutations in FUT8 (GenBank: NM_178155.2, Uniprot: Q9BYC5). Figure adapted and updated from Reference 9
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nasogastric tube (NG-tube). She has a history of severe
developmental delays with intellectual disability, along
with intractable seizures. Skeletal abnormalities include
short stature and scoliosis. She is noted to have congeni-
tal glaucoma (Table 1). CDG-0099 is still alive at 4 years
of age.
Finally, CDG-0108 is an affected female born to
healthy consanguineous parents of Southeast Asian
ancestry (Figure 1B). No complications or IUGR were
noted during pregnancy. She has significant hypotonia
and facial dysmorphism that includes a flattened nasal
bridge with short rounded tip and broad lips with a lower
lip that is everted. Like the previously mentioned sub-
jects, she has feeding problems with severe failure to
thrive, a history of global developmental delay with
severe intellectual disabilities, epilepsy, and microceph-
aly. A multitude of skeletal abnormalities were noted
including contractures of the fingers, ankles and feet,
progressive scoliosis and a history of left hip dislocations
(Table 1). Like those described above, CDG-0108 is still
alive at 16 years of age, making her the oldest known
FUT8-CDG case.
Comparing the three previously reported FUT8-CDG
cases, these four reveal striking similarities. All seven
individuals presented with severe global developmental
delays with cognitive impairment or intellectual disabil-
ity, feeding problems, dysmorphic facial features, micro-
cephaly, seizures, hypotonia, and various skeletal
abnormalities (Figure 2, Table 1). This suggests that
FUT8-CDG could have a recognisable phenotypic presen-
tation. Respiratory difficulties were also seen in 7/7 indi-
viduals with five of those seven having recurrent
infections (Figure 2, Table 1). This is noteworthy because
FUT8-KO mice also have respiratory difficulties.15 Car-
diac and renal abnormalities were less frequent and
could be due to other genetic factors. While all three orig-
inal cases presented with IUGR and ultimately died
prematurely, only one of the current four had IUGR and
all are still alive (Figure 2, Table 1).
In all four cases, clinical phenotyping and laboratory
testing failed to reach a definitive diagnosis. Therefore,
next-generation sequencing was used to reach a diagnosis.
3.2 | Molecular analysis
All four affected individuals had next generation
sequencing performed at different institutions or clinical
lab services. Three of the four individuals (0095, 0096,
0108) were from consanguineous families who had whole
exome performed on the proband (Table 1). For these
individuals, due to the consanguinity, filtering was ini-
tially focused on rare homozygous variants of less than
1% allele frequency. CDG-0099 had whole genome
sequencing performed on the family trio, which was
used to determine potential compound heterozygous,
homozygous, and de novo variants that segregated
appropriately.
Importantly, variant filtering revealed that three of the
four individuals (0095, 0099, 0108) were homozygous for
truncating loss of function INDEL or nonsense variants
in the alpha 1,6 fucosyltransferase FUT8 (NCBI Refseq—
NM_178155.2, Uniprot—Q9BYC5). CDG-0095 was identi-
fied to have a novel c.1302G > A [p.Trp434*], CDG-0099 a
novel c.1402delT [p.Ser468Hisfs*26] and CDG-0108
c.1675C > T [p.Arg559*] (Table 1, Figure 1B,C). Interest-
ingly, CDG-0096 was determined to be homozygous for a
variant of uncertain significance (VUS) c.716G > A [p.
R239Q], which overlaps with a previously reported non-
sense variant c.715C > T (p.Arg239*)9 (Table 1, Figure 1B,
C). Three in silico prediction programs suggest the
c.716G > A [p.R239Q] to be damaging with a Polyphen2
(http://genetics.bwh.harvard.edu/pph2/) score of 1 (proba-
bly damaging), SIFT (http://provean.jcvi.org/index.php)
FIGURE 2 Clinical Summary
for the three previously reported and
four new FUT8-CDG individuals
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score of 0 (deleterious), and a CADD (https://cadd.gs.
washington.edu/) score of 26.1 which would place it in the
top 0.5% of deleterious variants in the human genome.
Only the c.1675C > T [p.Arg559*] variant was seen in
a single heterozygous carrier from the gnomAD database
(1/250 464 alleles) (http://gnomad.broadinstitute.org/)
(gnomAD v2.1.1 accessed November 25, 2019) of 125 748
exomes and 15 708 whole-genomes of unrelated individ-
uals. Neither of the four variants were seen in gnomAD
v3, which is composed of 71 702 genomes (doi: https://
doi.org/10.1101/531210).
3.3 | Serum N-glycan analysis
We had previously used MALDI-TOF/TOF on serum
samples to confirm the lack of core fucosylation in indi-
viduals with FUT8-CDG.9 We applied this same tech-
nique to three of the four affected individuals presented
here. The lone individual (CDG-0099) we were unable to
obtain sample for and thus did not have MALDI-TOF/
TOF-MS of serum glycoproteins was homozygous for the
c.1402delT [p.Ser468Hisfs*26] (Table 1). We have previ-
ously shown that truncating variants in FUT8, like that
seen in CDG-0108, are not tolerated and results in the
complete loss of core fucosylation, ultimately causing
FUT8-CDG.9 When compared to a representative control
serum sample from a “healthy” individual, CDG-0095
and CDG-0108 who are both homozygous for nonsense
mutations, showed a complete loss of core fucosylated N-
glycans from serum proteins (Figure 3). MALDI-TOF/
TOF-MS values highlighted within red circles represent
those glycans that are completely missing in both CDG-
0095 and CDG-0108 (1836; 2040; 2081, 2244, 2606;
2967 m/z) (Figure 3). Importantly, CDG-0096, who
carries the VUS c.716G > A [p.R239Q] was also shown to
have a complete loss of core fucosylation (Figure 3).
Thus, confirming that the c.716G > A [p.R239Q] is in-
fact, a pathogenic variant. Finally, analysis of serum
transferrin glycosylation in at least one individual was
normal and did not reveal any clear abnormalities in
fucosylation (Figure S1). However, it should be noted
that only a small percentage of the total transferrin
undergoes fucosylation.
FIGURE 3 MALDI-TOF/TOF-MS N-glycan profiles from a healthy control serum sample as well as CDG-0095, 0096, 0108. Highlighted
within the red circles of the control sample, are those core fucosylated N-glycans that are completely lost in each of the three (0095, 0096,
0108) affected FUT8-CDG individuals
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4 | DISCUSSION
There are an estimated 13 fucosyltransferases encoded in
the human genome, but only one (FUT8) encodes an
enzyme capable of carrying out core fucosylation.3 The
importance of creating the FUT8-dependent core
fucosylation epitope can be seen in both mouse KO
models and individuals who have FUT8-CDG. Fut8 KO
mice show severe growth restriction, respiratory defects,
and a high mortality rate of ~70%.15 KO mice that do sur-
vive are more vulnerable to progressive chronic obstruc-
tive pulmonary disease and have been shown to exhibit a
significant reduction in liver regeneration capabilities
following partial hepatectomy.18,19 Additionally, they
display increased neuroinflammation and display
multiple behavioural abnormalities consistent with a
schizophrenia-like phenotype.13,20 Consistent with the
KO mouse model, affected individuals with FUT8-CDG
show severe developmental and growth delays, shortened
limbs, various neurological impairments, and respiratory
complications.9 Subsequent follow up of the original
reported cases revealed that all three have passed away,
while all four subjects described here are still alive at 3 to
16 years of age.
Interestingly, when heterozygous Fut8 +/− mice were
given L-fucose prior to partial hepatectomies, those that
received L-Fucose saw dramatically accelerated liver
regeneration.19 This likely occurred through increased
salvage-dependent synthesis of GDP-fucose. We had pre-
viously tested the effects of supplementing tissue culture
medium with L-fucose on FUT8-CDG fibroblasts, but we
saw no increase in total fucosylation.9 We considered L-
fucose supplementation with CDG-0096 since he had a
missense variant that could potentially have some resid-
ual activity. However, total N-glycan analysis of serum
showed that this individual was not capable of syn-
thesising any detectable core fucosylation (Figure 3). Pro-
viding fucose could potentially create a neo-antigen
specific for that individual and could precipitate a severe
immunological response. The family and physicians
decided the risks outweighed the potential benefits of
fucose supplementation.
In summary, FUT8-CDG is an extremely rare meta-
bolic disorder with only three documented cases who
present with a multitude of symptoms including IUGR,
severe delays in growth and development, severe neuro-
logical impairments, significantly shortened limbs, respi-
ratory complications, and decreased lifespan. Here, we
present on an additional four unrelated affected individ-
uals to expand both the molecular and clinical knowl-
edge for this disorder and highlight the usefulness of a
reliable serum biomarker for confirming FUT8-CDG
cases.
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